Catálogo de publicaciones - libros

Compartir en
redes sociales

Título de Acceso Abierto

The EBMT Handbook

Enric Carreras ; Carlo Dufour ; Mohamad Mohty ; Nicolaus Kröger (eds.)

7th ed. 2019.

Resumen/Descripción – provisto por la editorial

No disponible.

Palabras clave – provistas por la editorial

Hematology; Transplant Surgery; Blood Transfusion Medicine; Pediatric Surgery; Surgical Oncology

Disponibilidad
Institución detectada Año de publicación Navegá Descargá Solicitá
No requiere 2019 SpringerLink acceso abierto

Información

Tipo de recurso:

libros

ISBN impreso

978-3-030-02277-8

ISBN electrónico

978-3-030-02278-5

Editor responsable

Springer Nature

País de edición

Reino Unido

Fecha de publicación

Información sobre derechos de publicación

© EBMT and the Author(s) 2019

Cobertura temática

medicina-clinica

Medicina clínica

salud

Ciencias de la salud

Tabla de contenidos

doi: 10.1007/978-3-030-02278-5_60

Cellular Therapy with Engineered T Cells, Efficacy and Side Effects

Attilio Bondanza; Chiara Bonini; Boris Fehse; Michael Hudecek

The cellular basis of cancer immune surveillance, already hypothesized in ancient times, was only demonstrated with the advent of HSCT. Indeed, the discovery of the nature of GVHD and its antileukemic effects (Weiden et al.

Part VII - Prevention and Management of Relapse Topic leaders: Peter Bader and Nicolaus Kröger | Pp. 449-456

doi: 10.1007/978-3-030-02278-5_61

Mechanisms of Immune Resistance

Luca Vago; Francesco Dazzi

It is widely accepted that the curative potential of allo-HSCT for malignant diseases relies on the transfer of healthy donor immune cells capable of recognizing transplantation antigens on residual tumor cells (graft versus leukemia, GvL) and eliminating them.

Part VII - Prevention and Management of Relapse Topic leaders: Peter Bader and Nicolaus Kröger | Pp. 457-460

doi: 10.1007/978-3-030-02278-5_62

Regulatory Aspects of ATMP Versus Minimally Manipulated Immune Cells

Eoin McGrath; Christian Chabannon

Under current European regulations, hematopoietic cellular therapies fall under two categories: stem cell transplants and advanced therapy medicinal products (ATMPs).

Part VII - Prevention and Management of Relapse Topic leaders: Peter Bader and Nicolaus Kröger | Pp. 461-464

doi: 10.1007/978-3-030-02278-5_63

At-Home HSCT

Francesc Fernandez-Avilés; Gonzalo Gutiérrez-García

Toxicity and mortality associated with auto-HSCT have been reduced, and outpatient parenteral antimicrobial treatment has been proven feasible and safe, thanks to modern CVC and infusion devices.

Part VIII - Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester | Pp. 467-471

doi: 10.1007/978-3-030-02278-5_64

Umbilical Cord Blood Transplantation in Children and Adults

Jaime Sanz; Paul Veys; Vanderson Rocha

Umbilical cord blood transplantation (UCBT) from unrelated donors is a suitable option of HSCT for patients in whom it is indicated, and a suitable related or unrelated BM or PB donor is not available in due time.

Part VIII - Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester | Pp. 473-478

doi: 10.1007/978-3-030-02278-5_65

Haploidentical HSCT

Fabio Ciceri; Andrea Bacigalupo; Arjan Lankester; Alice Bertaina

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is now considered a clinical therapeutic option in patients candidate to allo-HSCT.

Part VIII - Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester | Pp. 479-486

doi: 10.1007/978-3-030-02278-5_66

Photopheresis in Adults and Pediatrics

Hildegard Greinix

Extracorporeal photopheresis (ECP) is a leukapheresis-based treatment that has been used during the last decades by many clinicians.

Part VIII - Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester | Pp. 487-491

doi: 10.1007/978-3-030-02278-5_67

Overweight and Obese Patients

Claudia Langebrake

“More obese people in the world than underweight” was the headline on BBC News on April 1, 2016.

Part VIII - Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester | Pp. 493-498

doi: 10.1007/978-3-030-02278-5_68

HSCT in Elderly Patients

Rafael F. Duarte; Isabel Sánchez-Ortega

The hematological malignancies which are the most common indications for auto- and allo-HSCT (e.g., AML/MDS, NHL, MM, and others) are diagnosed at a median age greater than 65 years old.

Part VIII - Specific Modalities of HSCT and Management Topic leaders: Andrew Gennery, Anna Sureda and Arjan Lankester | Pp. 499-503

doi: 10.1007/978-3-030-02278-5_69

Acute Myeloid Leukemia in Adults

Jurjen Versluis; Jan J. Cornelissen; Charles Craddock; Miguel Á. Sanz; Jonathan Canaani; Arnon Nagler

AML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts.

Part IX - Indications and Results Topic leaders: Rafael Duarte and Nicolaus Kröger | Pp. 507-521